(This document is an English translation of the Japanese language original.)

Nippon Kayaku Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, Japan; President: Koichiro Shimada) concluded the agreement on apaziquone (generic name) for non-muscle invasive bladder cancer (superficial bladder carcinoma and carcinoma in situ of bladder) with Spectrum Pharmaceuticals, Inc. (Irvine, California, USA; CEO: Rajesh C. Shrotriya) which is a commercial-stage biotechnology company with a primary focus in oncology on November 6, 2009. Nippon Kayaku received the exclusive rights to develop and commercialize apaziquone in Asia except South Korea.

Apaziquone is an anti-cancer agent that becomes activated by reductase enzymes found in cancer cells, and is specialized in the use of non-muscle invasive bladder cancer. The Phase 2 data held in the US has confirmed anti-tumor activity in patients with multiple, recurrent non-muscle invasive bladder cancer, showing 67% of a complete response after receiving six weekly treatments with 4 mg of apaziquone instilled into the urinary bladder. According to the apaziquone registration plan, which the U.S. Food and Drug Administration (FDA) concurred with under a Special Protocol Assessment, Spectrum and Allergan, Inc. (Irvine, California, USA, Chairman and CEO: David E.I. Pyott) are conducting the Phase 3 clinical studies and planning to complete the enrollment by year-end 2009. The FDA has also granted Fast Track Designation for the investigation of apaziquone for the treatment of non-muscle invasive bladder cancer. Next year Nippon Kayaku starts clinical development in Japan.

Now Nippon Kayaku sells 24 anti-cancer agents and 6 cancer supportive products, and is building a business platform focused on oncology area. Especially, as Nippon Kayaku has several products in urological cancer field, it is aiming at the enhancement of lineup by apaziquone and expects to contribute to the improvement of cancer therapy and happiness of patients, the families and the medical experts by marketing this medicine early.

【Summary of reference materials - Spectrum Pharmaceuticals, Inc.】

Company name	Spectrum Pharmaceuticals, Inc.
Location	Irvine, California, USA
Listed stock	NASDAQ（SPPI）
Business contents	The biotechnology company focused on development of medical products in oncology and urology. The Company has been already selling radioactive antibody (Zevalin) for malignant lymphoma and folate metabolism antagonist (Fusilev) for osteosarcoma.

Reference link

Spectrum Pharmaceuticals, Inc.

Sanofi-aventis K.K. (hereinafter: "sanofi-aventis"; Headquarters: Shinjuku, Tokyo; President: Patrick Chocat) and Nippon Kayaku Co., Ltd. (hereinafter: "Nippon Kayaku"; Headquarters: Chiyoda-ku, Tokyo; President: Koichiro Shimada) announced today that both companies agreed to transfer the marketing rights from Nippon Kayaku to sanofi-aventis on November 30, 2009 for the antineoplastic agent "ImmuCyst^® 81mg" [generic name: Freeze-dried Bacillus of Calmette and Guerin (BCG) for Intrvesical Use (Connaught strain)] for which Nippon Kayaku has the marketing approval in Japan. As a result, sanofi-aventis will become the sole marketer of this drug from December 1, 2009.

ImmuCyst^® is an antineoplastic agent with the Connaught strain of Bacillus Calmette-Guerin (BCG) as the active ingredient, developed by Connaught Laboratories in Canada (now Sanofi Pasteur, the vaccine division of the sanofi-aventis Group). In Japan, Nippon Kayaku obtained its marketing approval for treating superficial bladder cancer and carcinoma in situ (CIS) in October 2002. Out side of Japan, the drug is approved 52 countries around the world primarily for preventing the recurrence of superficial bladder cancer following transurethral resection, and for treating/preventing the recurrence of CIS.

(This document is an English translation of the Japanese language original.)

Nippon Kayaku Co., Ltd. (Chiyoda-ku, Tokyo; President: Koichiro Shimada) decided on June 17, 2008 to withdraw a Marketing Authorization Application (MAA) of Spanidin for the treatment of Wegener's granulomatosis*2.
The company recognized the difficulty in responding to assignments given in the course of examination of the MAA within an appropriate period of time, even though it had Euro Nippon Kayaku GmbH, its European subsidiary, serve as the applicant in the MAA to European Medicines Agency.

• *1INN : International Non-propriatary Name
• *2Wegener's granulomatosis : It is an autoimmune disease, accompanied by the antineutrophilic cytoplasmic antibody (ANCA). It is a systemic (more frequently occurring in the upper respiratory tract, lung and kidney) necrotizing/granulomatous angitis. Existing treatments permit recurrence in about 50% of cases, creating the potential for relapse. This refractory disease has no effective remedy, and requires a new treatment.

(This document is an English translation of the Japanese language original.)

Nippon Kayaku Co., Ltd. and Asahi Kasei Chemicals Corp. have concluded a basic agreement for the integration of their industrial explosives operations in a new equally held joint venture on January 2, 2008. Having reached basic accord regarding such an integration in May 2007, the two parties performed detailed analysis and discussions leading to the agreement announced today. Operating as an equity-method affiliate of both Nippon Kayaku and Asahi Kasei Chemicals, the joint venture will contribute to the development and growing profitability of its parent companies and their respective corporate groups.

The market for industrial explosives in Japan has been declining for several years with curtailment of investment in public works and fewer civil engineering projects, and these trends are projected to continue. The integration of operations will bring higher productivity through consolidation to achieve greater scale, and more efficient utilization of management resources through reduction of indirect costs, resulting in greater profitability. The combination of the technology and know-how of the two parties and their related subsidiaries will bring additional synergies for enhanced safety in the production and use of industrial explosives.

To effect the integration, the industrial explosives operations of Nippon Kayaku, including its wholly owned subsidiary Kayatech Co., Ltd., and those of Asahi Kasei Chemicals, including those of its wholly owned subsidiary Asahi Kasei Geotechnologies Co., Ltd., will be separated and transferred to Hokuyo Kayaku Co., Ltd., a wholly owned subsidiary of Nippon Kayaku. The company name of Hokuyo Kayaku will be changed prior to the integration, and Asahi Kasei Chemicals will obtain a 50% holding.

Profile of the new joint venture